Science and technology in the People's Republic of China

TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021

Retrieved on: 
Wednesday, August 4, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.

Key Points: 
  • Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM EDT.
  • The Company will host a conference call on Thursday, August 12, 2021, at 4:30 PM EDT to review the clinical, corporate and financial highlights.
  • Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
  • TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Pharmacy

DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.

Key Points: 
  • DEER PARK, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m.
  • The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 2454465.
  • Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Pharmaceuticals policy, Health care, Health, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Trademark, European Medicines Agency, NASDAQ, Mesoblast

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.
  • Expects to announce top-line results from the INTRIGUE Phase 3 study in the fourth quarter of 2021.
  • Expects potential approval from the European Medicines Agency (EMA) for QINLOCK in the fourth quarter of 2021.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry

The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.

Key Points: 
  • The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
  • And it's not just an "old-person" problem; nearly one in four adults aged 20 to 44 have high blood pressure.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space.
  • Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers.

Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Health care, Health, Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (CDC), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don't even know they have it. The urgency of finding effective treatments for this life-threatening disease can't be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
  • And it's not just an "old-person" problem; nearly one in four adults aged 20 to 44 have high blood pressure.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space.
  • Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers.

Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build

Retrieved on: 
Friday, July 30, 2021
Health care, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Articles, Forward-looking statement, Pharmaceutical industry in India

Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.

Key Points: 
  • Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.
  • The trilateral agreement was signed July 24, 2020 by representatives of Rafarma Pharmaceuticals, the Agency for the Development of the Pharmaceutical Industry of Uzbekistan and the Directorate for the Development of the Innovative Scientific and Production Pharmaceutical Cluster Tashkent Pharma Park.
  • The total investment will amount to $85 million (US), work on the project commences this year.
  • Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.

Universe Pharmaceuticals INC to Announce Unaudited Financial Results for The First Six Months of Fiscal Year 2021 on August 2, 2021

Retrieved on: 
Friday, July 30, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Health, Pharmacy

Jian, Jiangxi, China, July 30, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the Company) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens.

Key Points: 
  • Jian, Jiangxi, China, July 30, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the Company) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens.
  • The Company intends to file its financial results on Form 6-K with the Securities and Exchange Commission and release its earnings press release accordingly.
  • Universe Pharmaceuticals INC, headquartered in Jian, Jiangxi, China, is a pharmaceutical producer and distributor in China.
  • The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open.
  • ET to discuss its second quarter 2021 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Pharmaceutical industry, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health, Medication

BTIG Virtual Biotechnology Conference August 9-10, 2021

Key Points: 
  • BTIG Virtual Biotechnology Conference August 9-10, 2021
    If you are interested in arranging a one-on-one meeting, please contact your BTIG conference representative.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder.
  • To learn more about TFF Pharmaceuticals and its product candidates, visit the Companys website at https://tffpharma.com .

Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China

Retrieved on: 
Wednesday, July 28, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Novita

CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.

Key Points: 
  • CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.
  • In addition to excellent safety and pharmacokinetic profiles, NP-G2-044 has shown preliminary and exciting signals of efficacy in late-stage cancer patients.
  • "Novita is delighted to license our first-in-class fascin inhibitor to one of the largest pharmaceutical companies in China," said Jillian Zhang, Ph.D., President and Chief Scientific Officer of Novita.
  • About China Resources Double Crane Pharmaceutical Co., Ltd.
    China Resources Double Crane Pharmaceutical Co., Ltd. ("CRDC"), established in 1939 and headquartered in Beijing, China, has 21 subsidiaries and more than 11,000 employees throughout the country.